Andrew Hollman Meyer, Chief Business Officer at Janux Therapeutics, Inc. (JANX), sold 3,333 shares at $32.85 ($110K) on 2025-12-01, disclosed to the SEC on 2025-12-03.
Scheduled sale ($110k) by Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $32.85 | 2,700 | $89K | 80.7% |
| 2 | $33.52 | 633 | $21K | 19.3% |
| Total | $32.98 avg | 3,333 | $110K | 100% |
| Filing → |
| JANX | SELL | 2025-10-30 | $1.0M | — | Filing → |
| JANX | SELL | 2025-05-02 | $200K | — | Filing → |
| JANX | SELL | 2025-04-23 | $100K | — | Filing → |